The Pivot-or-Perish Odd Lot: From Crypto Plays to Desperate BiotechGlobal Report·2 days ago, 10:12 AMTGEN+5.78%CORZ+1.54%
Weekly Recap | BioAtla +13.64%, consensus target far above spotWeekly Review·Sep 12 at 07:41 AMBCAB-20.83%
The great biotech reshuffle: AI bets, survival pivots, and buyout rumorsGlobal Report·Sep 9 at 10:11 AMJAZZ+0.10%BCAB-20.83%
The Infrastructure Reality Check: From Data Center Power to Capital ConstraintsGlobal Report·Sep 1 at 11:32 AMFPS+9.24%EXC+0.47%
Satellogic and Humana Lead Q2 2026 Earnings Beats Across Niche US EquitiesGlobal Report·Sep 1 at 10:13 AMUVV-0.49%BCAB-20.83%
End of Q2 2026: How 10 Off-the-Radar Stocks Are Performing This WeekGlobal Report·Sep 1 at 09:18 AMEDU-0.50%AS-3.17%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Aug 28 at 05:05 PMQNRX+1.59%PPCB-0.79%
BioAtla shares are trading lower after Nasdaq moved to delist the company, with trading suspended August 31 ahead of a transition to OTC Markets.benzinga_article·Aug 28 at 03:08 PMBCAB-20.83%
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga_article·Aug 28 at 12:06 PMQNRX+1.59%BTAI0.00%
BioAtla faces Nasdaq delisting after listing council affirms suspension decisionPUBT·Aug 28 at 12:03 PMBCAB-20.83%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Aug 27 at 12:05 PMACIU+1.13%VNRX+3.64%
Crypto Leaps, Chip Sales Surge, and Biotech Cuts: Periphery Assets Navigate 2026Global Report·Aug 25 at 10:12 AMSIMO+5.04%BNKK+7.81%
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga_article·Aug 21 at 09:06 PMHSCS+27.70%PMI-13.58%
BCAB: Q2 2026 net income driven by $6.5M licensing revenue, but going concern risks persistQuartr·Aug 13 at 09:07 PMBCAB-20.83%
BioAtla Q2 FY26 swings to net income of $452,000; revenue rises to $6.5 millionPUBT·Aug 13 at 09:02 PMBCAB-20.83%
